Patents by Inventor Albert Robichaud

Albert Robichaud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indolylalkylpyridin-2-amines for the inhibition of beta-secretase
    Publication number: 20080076801
    Abstract: The present invention provides an indolylalkylpyridin-2-amine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 27, 2008
    Applicant: Wyeth
    Inventors: Yinfa Yan, Ping Zhou, Yi Fan, Albert Robichaud, Michael Malamas
  • PYRIMIDOINDOLONES AND METHODS FOR USING SAME
    Publication number: 20070270587
    Abstract: Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.
    Type: Application
    Filed: July 2, 2007
    Publication date: November 22, 2007
    Applicant: Wyeth
    Inventors: Paul Dollings, Arlene Dietrich, Lisa Havran, Chae-Koo Chong, Donna Huryn, Albert Robichaud, Boyd Harrison, Wayne Childers, Alexander Greenfield, James Bicksler, Vasilios Marathias
  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Publication number: 20070232618
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: May 15, 2007
    Publication date: October 4, 2007
    Applicant: Wyeth
    Inventors: Ronald Bernotas, Yinfa Yan, Albert Robichaud, Guangcheng Liu
  • Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase
    Publication number: 20070072925
    Abstract: The present invention provides a 2-amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: September 25, 2006
    Publication date: March 29, 2007
    Applicant: Wyeth
    Inventors: Michael Malamas, James Erdei, William Fobare, Dominick Quagliato, Schuyler Antane, Albert Robichaud
  • Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20070054896
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: August 14, 2006
    Publication date: March 8, 2007
    Applicant: Wyeth
    Inventors: Hassan Elokdah, Alexander Greenfield, Kevin Liu, Geraldine McFarlane, Cristina Grosanu, Jennifer Lo, Albert Robichaud
  • Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20070037802
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: August 14, 2006
    Publication date: February 15, 2007
    Applicant: Wyeth
    Inventors: Hassan Elokdah, Alexander Greenfield, Kevin Liu, Robert McDevitt, Geraldine McFarlane, Cristina Grosanu, Jennifer Lo, Yanfang Li, Albert Robichaud, Ronald Bernotas
  • Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
    Publication number: 20070004730
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles
    Type: Application
    Filed: June 29, 2006
    Publication date: January 4, 2007
    Applicant: Wyeth
    Inventors: Ping Zhou, Michael Malamas, Yanfang Li, Albert Robichaud, Dominick Quagliato
  • Substituted heterocyle fused gamma-carbolines
    Publication number: 20060178362
    Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Application
    Filed: March 15, 2006
    Publication date: August 10, 2006
    Inventors: Albert Robichaud, Taekyu Lee, Wei Deng, Ian Mitchell, Wenting Chen, Christopher McClung, Emilie Calvello, David Zawrotny
  • Amino-pyridines as inhibitors of beta-secretase
    Publication number: 20060173049
    Abstract: The present invention provides an amino-pyridine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: January 31, 2006
    Publication date: August 3, 2006
    Applicant: Wyeth
    Inventors: Michael Malamas, William Fobare, William Solvibile, Frank Lovering, Jeffrey Condon, Albert Robichaud
  • Substituted heterocycle fused gamma-carbolines
    Publication number: 20060148808
    Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
    Type: Application
    Filed: March 14, 2006
    Publication date: July 6, 2006
    Inventors: Albert Robichaud, Taekyu Lee, Wei Deng, Ian Mitchell, Michael Yang, Simon Haydar, Wenting Chen, Christopher McClung, Emilie Calvello, David Zawrotny
  • Pyrimidoindolones and methods for using same
    Publication number: 20050250798
    Abstract: Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed.
    Type: Application
    Filed: February 18, 2005
    Publication date: November 10, 2005
    Applicant: Wyeth
    Inventors: Paul Dollings, Arlene Dietrich, Lisa Havran, Chae-Koo Chong, Donna Huryn, Albert Robichaud, Boyd Harrison, Wayne Childers, Alexander Greenfield, James Bicksler
  • Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
    Publication number: 20050239768
    Abstract: The present application provides novel compounds according to Formula (I): including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R1, R4a, R5, R6, R7, R8, R9, m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).
    Type: Application
    Filed: April 13, 2005
    Publication date: October 27, 2005
    Inventors: Taekyu Lee, Wei Deng, Albert Robichaud
  • Substituted pyridoindoles as serotonin agonists and antagonists
    Patent number: 6699852
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 2, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert Robichaud, John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands
    Patent number: 6638934
    Abstract: The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R4b, R5, R6, R7, R8, R9, n, and X are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: October 28, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert Robichaud, Ian S. Mitchell, Taekyu Lee, Wenting Chen
  • Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands
    Publication number: 20020177596
    Abstract: The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): 1
    Type: Application
    Filed: December 19, 2001
    Publication date: November 28, 2002
    Inventors: Albert Robichaud, Ian S. Mitchell, Taekyu Lee, Wenting Chen
  • Substituted pyridoindoles as serotonin agonists and antagonists
    Publication number: 20020173503
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) 1
    Type: Application
    Filed: December 19, 2001
    Publication date: November 21, 2002
    Inventors: Albert Robichaud, John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
  • Phenyl spiroethercycloalkyl tachykinin receptor antagonists
    Patent number: 5877191
    Abstract: The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, m, n and the dashed lines are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: March 2, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Charles G. Caldwell, Yuan-Ching Chiang, Conrad Dorn, Paul Finke, Jeffrey Hale, Malcolm Maccoss, Sander Mills, Albert Robichaud
  • Cycloalkyl tachykinin receptor antagonists
    Patent number: 5750549
    Abstract: The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.
    Type: Grant
    Filed: October 15, 1996
    Date of Patent: May 12, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Charles G. Caldwell, Ping Chen, Philippe L. Durette, Paul Finke, Jeffrey Hale, Edward Holson, Ihor Kopka, Malcolm MacCoss, Laura Meurer, Sander G. Mills, Albert Robichaud